EP-0062 is under clinical development by Ellipses Pharma and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EP-0062’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EP-0062 is under development for the treatment of relapsed locally advanced or metastatic AR positive / HER-2 negative / ER positive breast cancer. It is administered through oral route.
Ellipses Pharma overview
Ellipses Pharma is a drug development company focused on the advancement of innovative cancer treatments through the clinic. The company has developed a technology platform to access best oncology drug assets for further investigation, analysis and clinical development. Ellipses Pharma provides a permanent source of capital for the development of cancer assets and conducts multiple oncology clinical trials in parallel supported by Scientific Affairs Group. The company is building relationships with research institutions, charitable bodies, pharmaceutical, biotechnology companies, and outsourced development providers for delivering more treatment options in oncology. Ellipses Pharma is headquartered in London, England, the UK.
For a complete picture of EP-0062’s drug-specific PTSR and LoA scores, buy the report here.